Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.
Amylin Products for Obesity and Diabetes Research
AMY/CALCR MOA-reflective Assays to Accelerate Next-generation Therapeutics Development for Obesity and Diabetes
Amylin (AMY) receptors are heterodimeric complexes formed by the calcitonin (CALCR or CT) receptor in association with receptor activity-modifying proteins (RAMPs). These class B GPCRs are critical regulators of satiety, gastric emptying, glucose homeostasis, and overall energy balance. Due to their pivotal role in metabolic control, amylin receptors have become highly attractive therapeutic targets for the treatment of obesity and type 2 diabetes, especially in combination with GLP-1 receptor agonists. Recent advances highlight the importance of AMYRs in next-generation metabolic disease therapies, with investigational drugs exploring their synergy in enhancing weight loss and glycemic control.
To support these research efforts, Eurofins DiscoverX provides a suite of cell-based assays for AMY and CALCR receptor signaling, covering both cAMP accumulation and β-arrestin recruitment pathways. These pathway-reflective cell line assays enable researchers to profile ligand activity, assess biased signaling, and characterize receptor pharmacology with high reproducibility. These assays have direct clinical relevance to targeted therapies for metabolic disease and related indications, where fine-tuned signaling profiles at AMY- and CALCR-containing receptor complexes can translate into differentiated efficacy and tolerability.
Eurofins DiscoverX offers amylin and calcitonin receptor cAMP and β-arrestin assays in several convenient formats - stable cell lines, eXpress assay kits, and membrane preps. These formats support key stages of drug discovery and development, from primary screening and detailed pharmacological profiling to characterization of signaling mechanisms, enabling the identification and characterization of AMY- and CALCR-targeted therapeutics for obesity and metabolic diseases.
Product Highlights
- Comprehensive AMYR Assay Portfolio – Cell line assays, eXpress assay kits, membrane preparations, and detection reagents for drug discovery and development
- Multiple MOA Formats – Measure ligand activity across cAMP signaling and β-arrestin recruitment for a complete pharmacological profile
- Integrated GPCR Solutions – Complementary products to GLP1R and GIPR assays, supporting combination therapy research in obesity and metabolic disease
Products
cAMP
β-Arrestin
Resources
Related Pages
Products
Eurofins DiscoverX provides a full suite of amylin and calcitonin receptor to support drug discovery, including human and ortholog cell line assays, ready-to-use eXpress Kits and membrane preparations.
Product Types
- AMY/CALCR Cell Line Assays - Complete assays that include stable cell lines (continuous culture) developed to reflect the target’s mechanism of action (cAMP and β-arrestin) with a drugs’ interaction in a standard cell line background.
- AMY/CALCR eXpress Assay Kits - Ready-to-use cell-based assay kits for quick analysis and implementation in early discovery phases for screening applications, proof-of-concept, MOA confirmation (cAMP and β-arrestin), and rank-ordering studies.
- AMY/CALCR Membrane Preparations - Derived from proprietary stable recombinant cells ensuring high levels of receptor surface expression. Ideal for screening ligand binding affinities.
- Early Access Products - Obtain early access to products before they are officially released. These products help scientific researchers eager to evaluate and shape the latest assay platforms.
Applications
- AMY/CALCR cAMP Assays - Explore a full suite of products designed to quantify cAMP in response to AMY and CALC receptor activation.
- AMY/CALCR β-Arrestin Assays - Characterize AMY and CALC receptor function and ligand bias with β-arrestin cell line assays and eXpress assay kits.
The Amylin Receptor Complex
Amylin (islet amyloid polypeptide) is a peptide hormone co-secreted with insulin that regulates glucose homeostasis by slowing gastric emptying, suppressing glucagon secretion, and promoting satiety, making it a compelling drug target for the treatment of obesity and diabetes. Unlike many peptide receptors, the functional amylin receptor is a unique heteromeric complex. The receptor is formed by the association of the calcitonin receptor (CALCR) with one of three Receptor Activity-Modifying Proteins (RAMPs), a crucial insight for effectively targeting amylin's physiological actions.
Formation of amylin receptor complexes. The calcitonin receptor (CALCR) combines with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3) to generate distinct amylin receptors: AMY1, AMY2, and AMY3, respectively.
Understanding and precisely characterizing compound interactions with these specific receptor subtypes is critical for developing highly effective and selective amylin-based therapeutics. Eurofins DiscoverX assay solutions are designed to precisely dissect these interactions, empowering your research into this vital metabolic pathway.